<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 31-year-old woman with <z:e sem="disease" ids="C0856536" disease_type="Neoplastic Process" abbrv="">Philadelphia chromosome-positive</z:e> <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>) was treated intermittently with high-dose busulphan over a 6-yr period (total dose 1320 mg) </plain></SENT>
<SENT sid="1" pm="."><plain>3 yr later (after receiving no further cytotoxic drugs) she developed <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> and marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath> of relatively abrupt <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Transfusion of reconstituted blood-derived stem cells (collected 7 yr previously) re-established <z:hpo ids='HP_0011010'>chronic</z:hpo> phase <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>These events are more consistent with 'stem cell exhaustion' than with an acquired marrow microenvironmental defect occurring in the course of <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>The contribution of busulphan is uncertain </plain></SENT>
</text></document>